Drug Trial Radar · NCT04787042
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Last checked: Nov 19, 2026Latest source record: Nov 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
316
Planned (sponsor's estimate)
Start
Aug 6, 2021
Primary completion
Jun 30, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Simcha IL-18, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Mar 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned; the exact design of the Phase 2 study elements with respect to formulation and pre-treatment will be determined after completion of the Phase 1 study portion of the trial.
Conditions
- Cancer
- Solid Tumor
- Melanoma
- Renal Cell Carcinoma
- Triple-negative Breast Cancer
- Non Small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Carcinoma
- MSI-High
Interventions
ST-067Biological
ST-067 is an engineered variant of human interleukin-18.
Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]Biological
Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.
pembrolizumabBiological
Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the maximum tolerated dose of ST-067 in phase 1a monotherapyTime frame: Day 29
- Evaluate the overall safety and tolerability of ST-067 in combination with pembrolizumabTime frame: Day 29
- Number of Participants With Treatment-Related Adverse EventsTime frame: Day 29
- Initial assessment of efficacy in phase 2Time frame: At 8 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona · Recruiting
Sarah Cannon Research Institute at HealthONE
Denver, Colorado · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.